Staar Surgical price target raised to $26 from $21 at Wedbush

Wedbush raised the firm’s price target on Staar Surgical (STAA) to $26 from $21 and keeps a Neutral rating on the shares. The firm notes Staar announced that it expects preliminary net sales for Q1 to be in excess of $90M, citing that the company’s largest market, China, accounted for the majority of the increase along with continued double-digit growth in the Americas. While Wedbush was surprised by the timing of this announcement due to the fact that the company did not provide FY26 guidance or color on Q1 on its recent earnings call, the firm is not surprised by the China rebound itself.